Comparing the current results to its competitors, Rafael Holdings Inc reported Revenue decrease in the 3 quarter 2026 year on year by -50.55 %, despite the revenue increase by the most of its competitors of 4.93 %, recorded in the same quarter.
Rafael Holdings Inc, slower than the average decrease reported by the company's competitors of -25.25 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -25.25 %
Rafael Holdings Inc's Comment on Competition and Industry Peers
The company and its portfolio companies operate in highly competitive sectors, facing competition from commercial pharmaceutical, biotechnology, and medical device companies, as well as academic institutions, government agencies, and private and public research organizations. Many competitors possess greater financial resources and capabilities in product development, manufacturing, and marketing. Large pharmaceutical and medical device firms have extensive experience in development, clinical testing, and regulatory approval processes. Universities and research institutes also compete in research activities and in recruiting scientific and clinical personnel. Smaller or early-stage companies may be significant competitors, particularly through collaborations with larger firms. Competitors are developing or acquiring pharmaceuticals, medical devices, and over-the-counter products targeting similar diseases and unmet medical needs. The introduction of new products or delivery systems by competitors that offer therapeutic or cost advantages could result in price reductions or decreased sales volume for the company and its portfolio companies.
Catalyst Pharmaceuticals Inc operates under a business model where it develops and commercializes novel drugs to address unmet medical needs primarily in the field of rare diseases. The company focuses on conducting clinical research, obtaining necessary regulatory approvals, and marketing its products to healthcare professionals and patients. Catalyst Pharmaceuticals Inc aims to generate revenue through the sale of its approved drugs and by seeking partnerships or collaborations for the development and commercialization of new products.
Kala Pharmaceuticals Inc operates on a business model that revolves around the development and commercialization of innovative ophthalmic therapeutics to address unmet needs in eye care. Their approach focuses on utilizing their proprietary mucus-penetrating particle (MPP) technology to enhance drug delivery and improve patient outcomes. By leveraging partnerships and collaborations with industry stakeholders, Kala Pharmaceuticals aims to bring novel therapies to market and improve the standard of care for various eye diseases.
Vanda Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of innovative therapies for central nervous system disorders. Their business model revolves around conducting research and development activities to identify potential drug candidates, securing intellectual property rights, and seeking regulatory approvals for the commercialization of their products. Through partnerships and collaborations, they aim to bring their novel therapies to market and improve the lives of patients suffering from neurological disorders.
Sources:
Rafael Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Rafael Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
